2024
Author Correction: TLR agonists polarize interferon responses in conjunction with dendritic cell vaccination in malignant glioma: a randomized phase II Trial
Everson R, Hugo W, Sun L, Antonios J, Lee A, Ding L, Bu M, Khattab S, Chavez C, Billingslea-Yoon E, Salazar A, Ellingson B, Cloughesy T, Liau L, Prins R. Author Correction: TLR agonists polarize interferon responses in conjunction with dendritic cell vaccination in malignant glioma: a randomized phase II Trial. Nature Communications 2024, 15: 4800. PMID: 38839763, PMCID: PMC11153605, DOI: 10.1038/s41467-024-48995-7.Peer-Reviewed Original Research
2017
NIMG-36. DELINEATION OF IMMUNE RESPONSES AFTER IMMUNOTHERAPY IN GLIOBLASTOMA USING PET AND MRI
Soto H, Antonios J, Everson R, Moughon D, Wang A, Orpilla J, Radu C, Ellingson B, Lee J, Cloughesy T, Phelps M, Czernin J, Liau L, Prins R. NIMG-36. DELINEATION OF IMMUNE RESPONSES AFTER IMMUNOTHERAPY IN GLIOBLASTOMA USING PET AND MRI. Neuro-Oncology 2017, 19: vi149-vi150. PMCID: PMC5692246, DOI: 10.1093/neuonc/nox168.611.Peer-Reviewed Original ResearchPD-1Dendritic cellsMAb blockadeContrast enhancementHost anti-tumor immune responseTreated with dendritic cellsAnti-tumor immune responseInflammatory responseClinical management of patientsDendritic cell vaccinesTumor-infiltrating lymphocytesSyngeneic immunocompetent miceTreated with immunotherapyCo-registration of PETSecondary lymphoid organsContrast-enhanced MRIManagement of patientsProbe uptakePET probeImmune inflammatory responseNon-invasive modalityNon-invasive imaging techniqueImmunocompetent micePre-contrast T1Cell vaccine